• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CHRNA2 Gene Record

  • Summary
  • Interactions
  • Claims
  • CHRNA2 1135 Druggable Genome

    Alternate Names:

    1135
    CHOLINERGIC RECEPTOR NICOTINIC ALPHA 2 SUBUNIT
    CHRNA2
    118502
    1956
    ENSG00000120903
    OTTHUMG00000102083
    Q15822
    ACHA2_HUMAN
    BE0000738
    NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA-2
    NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA-2 SUBUNIT PRECURSOR. [SOURCE:UNIPROT/SWISSPROT;ACC:Q15822]
    463
    nicotinic acetylcholine receptor α2 subunit
    Neuronal acetylcholine receptor alpha-2
    T55815
    NM_000742
    NP_000733

    Gene Info:

    Target Main Class Receptors
    Target Subclass Ligand_gated_ion_channels
    Target Subclass cys-loop
    Transmembrane Helix Count 4
    Target Subclass Channels
    Target Class Receptors
    Target Subclass TC:1.A.9
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Interpro Type Domain
    Interpro Short Name Neur_channel
    Interpro Name Neurotransmitter-gated ion-channel
    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR006202
    Interpro Type Family
    Interpro Short Name Neur_chan_lig-bd
    Human Readable Name ION CHANNEL
    Interpro Acc IPR006201
    Interpro Name Neurotransmitter-gated ion-channel ligand-binding
    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name Nicotinic acetylcholine receptors
    GuideToPharmacology Gene Category ID 76
    (6 More Sources)

    Gene Categories: Category Details

    ION CHANNEL
    DRUGGABLE GENOME

    Publications:

    An et al., 2010, Acetylcholine negatively regulates development of the neuromuscular junction through distinct cellular mechanisms., Proc. Natl. Acad. Sci. U.S.A.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Jonsson Fagerlund et al., 2009, Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor., Anesthesiology
    Jonsson et al., 2006, Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade., Anesthesiology
    Liu et al., 2008, Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors., Anesth. Analg.
    Zhou X et al., 2002, Pharmacological properties of nicotinic acetylcholine receptors expressed by guinea pig small intestinal myenteric neurons., J Pharmacol Exp Ther
    Loiacono et al., 1993, Multiple binding sites for nicotine receptor antagonists in inhibiting [3H](-)-nicotine binding in rat cortex., Neuropharmacology
    Kárpáti et al., 2002, [Investigation of neuromuscular blocking agents at Richter Ltd]., Acta Pharm Hung
    Töröcsik et al., 1991, Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus., Eur. J. Pharmacol.
    Kiss et al., 1997, Dual effect of DMPP on the resting release of noradrenaline from rat hippocampal slices., Brain Res. Bull.
    Wenningmann et al., 2001, The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium., Mol. Pharmacol.
    Nishimura et al., 2010, Analysis of motor function modulated by cholinergic neurons in planarian Dugesia japonica., Neuroscience
    Aoshima et al., 1992, Inhibition of ionotropic neurotransmitter receptors by antagonists: strategy to estimate the association and the dissociation rate constant of antagonists with very strong affinity to the receptors., J. Biochem.
    Wang et al., 2010, The effect of local anesthetics on the inhibition of adult muscle-type nicotinic acetylcholine receptors by nondepolarizing muscle relaxants., Eur. J. Pharmacol.
    Lee et al., 2002, Molecular conformation-activity relationship of decamethonium congeners., Br J Anaesth
    Maneckjee et al., 1994, Opioids induce while nicotine suppresses apoptosis in human lung cancer cells., Cell Growth Differ.
    Tuba et al., 2002, Synthesis and structure-activity relationships of neuromuscular blocking agents., Curr. Med. Chem.
    Ihmsen et al., 2009, Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy., Anesthesiology
    Struthers et al., 2009, Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine., Pharmacol. Biochem. Behav.
    Shytle et al., 2002, Mecamylamine (Inversine): an old antihypertensive with new research directions., J Hum Hypertens
    Lee et al., 2006, Effects of dextrorotatory morphinans on alpha3beta4 nicotinic acetylcholine receptors expressed in Xenopus oocytes., Eur. J. Pharmacol.
    Damaj et al., 2005, Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity., J. Pharmacol. Exp. Ther.
    Dilger et al., 2007, Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists., Anesthesiology
    Mansvelder et al., 2009, Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits., Semin. Cell Dev. Biol.
    Narahashi et al., 2000, Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior., Toxicol. Sci.
    Jackson et al., 2010, Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice., J. Pharmacol. Exp. Ther.
    Zaniewska et al., Nicotine dependence - human and animal studies, current pharmacotherapies and future perspectives., Pharmacol Rep
    Sullivan et al., 2004, Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics., Am. J. Med. Genet. B Neuropsychiatr. Genet.
    Paul et al., 2002, Characterization of the interactions between volatile anesthetics and neuromuscular blockers at the muscle nicotinic acetylcholine receptor., Anesth. Analg.
    Liu et al., 2009, Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor., Mol. Pharmacol.
    Groebe et al., 1994, Irreversible inhibition of nicotinic acetylcholine receptors by the bipinnatins. Toxin activation and kinetics of receptor inhibition., J. Biol. Chem.
    Wang et al., 2003, Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain., J. Biol. Chem.
    Iwatsuki et al., 1980, Inotropic effects of non-depolarizing muscle relaxants in isolated canine heart muscle., Anesth. Analg.
    Hendrickson et al., 2013, Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence., Front Psychiatry
    Dopico et al., 2009, Acute alcohol action and desensitization of ligand-gated ion channels., Pharmacol. Rev.
    García-Colunga J et al., 1997, Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac)., Proc Natl Acad Sci U S A
    Stauderman KA et al., 1998, Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha2beta4, alpha3beta4 and alpha4beta4 stably expressed in HEK293 cells., J Pharmacol Exp Ther
  • CISATRACURIUM   CHRNA2

    Interaction Score: 10.52

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    12171561 17139284 17016423


    Sources:
    TTD DrugBank

  • METOCURINE   CHRNA2

    Interaction Score: 8.42

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    18842832 8132625 11752352 12799358 18633030


    Sources:
    TEND TdgClinicalTrial DrugBank

  • DOXACURIUM   CHRNA2

    Interaction Score: 7.36

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11752352 17139284 17016423 18633030


    Sources:
    TEND TdgClinicalTrial DrugBank

  • PIPECURONIUM   CHRNA2

    Interaction Score: 6.31

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12426786 1748153 11752352 9227834 17016423


    Sources:
    TEND TdgClinicalTrial TTD DrugBank

  • VECURONIUM   CHRNA2

    Interaction Score: 5.26

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    12145052 19417616 18633030


    Sources:
    TTD DrugBank

  • MIVACURIUM   CHRNA2

    Interaction Score: 5.26

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    19417616 11752352 17139284 16931985 17016423 19352159


    Sources:
    TEND TdgClinicalTrial TTD DrugBank

  • ROCURONIUM   CHRNA2

    Interaction Score: 3.51

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name rocuronium bromide,Esmeron, Zemuron, Eslax
    Novel drug target Established target

    PMIDs:
    19417616 11752352 17139284 16931985 17016423 18633030


    Sources:
    TEND TdgClinicalTrial TTD DrugBank

  • TUBOCURARINE   CHRNA2

    Interaction Score: 2.89

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11562442 20338223 19417616 11752352 17139284 17016423 18633030


    Sources:
    TEND TdgClinicalTrial TTD DrugBank

  • DECAMETHONIUM   CHRNA2

    Interaction Score: 2.81

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12067008 7848904 11752352 17139284 17016423


    Sources:
    TEND TdgClinicalTrial DrugBank

  • PANCURONIUM   CHRNA2

    Interaction Score: 2.52

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    19417616 17016423 17525594


    Sources:
    TEND TdgClinicalTrial DrugBank

  • METOCURINE IODIDE   CHRNA2

    Interaction Score: 2.1

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11752352 6107062 17139284 17016423 18633030


    Sources:
    DrugBank

  • HEXAMETHONIUM   CHRNA2

    Interaction Score: 2.1

    Interaction Types & Directionality:
    antagonist (inhibitory)
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand None

    PMIDs:
    12183644 8232788


    Sources:
    DrugBank GuideToPharmacology

  • CARBACHOL   CHRNA2

    Interaction Score: 2.1

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    20498043 11752352 17139284 17016423


    Sources:
    TEND TdgClinicalTrial TTD

  • MECAMYLAMINE   CHRNA2

    Interaction Score: 1.72

    Interaction Types & Directionality:
    antagonist (inhibitory)
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name AGI-004, mecamylamine transdermal patch, CR
    Novel drug target Established target
    Trial Name mecamylamine HCl , TC-5231

    PMIDs:
    11752352 17139284 17016423 19778551 12080428


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology

  • BIPERIDEN   CHRNA2

    Interaction Score: 1.2

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17139284 17016423


    Sources:
    TEND TdgClinicalTrial

  • LEVALLORPHAN   CHRNA2

    Interaction Score: 1.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • GANTACURIUM   CHRNA2

    Interaction Score: 1.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name gantacurium chloride
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • ATRACURIUM   CHRNA2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TEND TdgClinicalTrial

  • GALLAMINE TRIETHIODIDE   CHRNA2

    Interaction Score: 0.7

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    1337082 17139284 17016423


    Sources:
    DrugBank

  • CP-601927   CHRNA2

    Interaction Score: 0.7

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Details of the Assay for Interaction Measured against α2β4 nAchRs- species not identified.
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • EPIBATIDINE   CHRNA2

    Interaction Score: 0.6

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    9454827


    Sources:
    DrugBank

  • DEXTROMETHORPHAN   CHRNA2

    Interaction Score: 0.53

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    16563374 15356218 17139284 17016423


    Sources:
    DrugBank

  • PROCAINE   CHRNA2

    Interaction Score: 0.32

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    20045405


    Sources:
    DrugBank

  • NICOTINE   CHRNA2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    19560048 11006350 20400469 20081230 15048644


    Sources:
    TEND TdgClinicalTrial DrugBank

  • CYTISINICLINE   CHRNA2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • FLUOXETINE   CHRNA2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    9050901


    Sources:
    DrugBank

  • ALCOHOL   CHRNA2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23641218 19270242


    Sources:
    DrugBank

  • Ensembl: ENSG00000120903

    • Version: 101_38

    Alternate Names:
    CHRNA2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000120903

    • Version: 26-July-2011

    Alternate Names:
    NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA-2 SUBUNIT PRECURSOR. [SOURCE:UNIPROT/SWISSPROT;ACC:Q15822] Description
    CHRNA2 Display Id
    ENSG00000120903 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: Q15822

    • Version: 11-September-2012

    Alternate Names:
    ACHA2_HUMAN Uniprot Id
    1135 Entrez Gene Id
    CHRNA2 Uniprot Gene Name

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Interpro Type Domain

    Gene Categories:
    ION CHANNEL, DRUGGABLE GENOME

    Publications:

  • TEND: Q15822

    • Version: 01-August-2011

    Alternate Names:
    CHRNA2 Gene Symbol
    Q15822 Uniprot Accession
    ENSG00000120903 Ensembl Gene Id

    Gene Info:
    Target Main Class Receptors
    Target Subclass Ligand_gated_ion_channels
    Target Subclass cys-loop

    Publications:

  • TdgClinicalTrial: Q15822

    • Version: January-2014

    Alternate Names:
    CHRNA2 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass TC:1.A.9

    Publications:

  • GuideToPharmacology: 1135

    • Version: 29-September-2020

    Alternate Names:
    1956 HUGO Gene ID
    1956 HUGO Gene Symbol
    cholinergic receptor nicotinic alpha 2 subunit HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name Nicotinic acetylcholine receptors
    GuideToPharmacology Gene Category ID 76

    Gene Categories:
    ION CHANNEL

    Publications:

  • DrugBank: BE0000738

    • Version: 5.1.7

    Alternate Names:
    CHRNA2 DrugBank Gene Name
    Q15822 UniProt Accession
    1135 Entrez Gene Id

    Gene Info:

    Publications:
    Mansvelder et al., 2009, Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits., Semin. Cell Dev. Biol.
    Narahashi et al., 2000, Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior., Toxicol. Sci.
    Jackson et al., 2010, Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice., J. Pharmacol. Exp. Ther.

  • HingoraniCasas: ENSG00000120903

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000120903 Gene Symbol
    CHRNA2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Pharos: CHRNA2

    • Version: 03-September-2020

    Alternate Names:
    Neuronal acetylcholine receptor subunit alpha-2 Gene Name
    Q15822 UniProt ID

    Gene Info:

    Gene Categories:
    ION CHANNEL

    Publications:

  • TTD: Neuronal acetylcholine receptor alpha-2

    • Version: 2020.06.01

    Alternate Names:
    CHRNA2 TTD Gene Abbreviation
    T55815 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21